Association of polymorphism of Enzyme Thiopurine Methyl Transferase in Head & Neck Squamous Cell Cancer and treatment response to Concurrent Chemo Radiotherapy

Title: Association of polymorphism of Enzyme Thiopurine Methyl Transferase in Head & Neck Squamous Cell Cancer and treatment response to Concurrent Chemo Radiotherapy

Authors: Sandip Barik, Sudhir Singh, Seema Gupta, Naseem Jamal, Devendra Parmar, Ankur Dhawan, MLB Bhatt

DOI: https://dx.doi.org/10.18535/jmscr/v5i4.177

Abstract

Objectives: The aim of the present study was to determine the frequency of the functional TPMT polymorphisms and their association with the treatment outcome in patients of HNSCC receiving cisplatin based chemoradiation.

Methods: 100 patients of locally advanced head & neck squamous cell carcinoma and 100 controls frequently matched with cases were enrolled in the study. Allelic variant of TPMT gene was done with the help of RFLP PCR analysis. All patients received radiation 70 Gy with concurrent cisplatin 35 mg/m²every weekly. Response assessment was done with help of World Health Organization (W.H.O.).

Results: Majority of Indian population had TPMT*3B wild genotype. The patients carrying the wild type genotype of all four alleles responded to Chemoradiation, while TPMT*3B heterotypes and TPMT *3C homozygous mutant form were found among the non responder patients.

Conclusion: Genotyping of TPMT helps us to identify responders and non responders to standard treatment and enhances the precision regarding selection of treatment modality.

Keywords: Head and Neck Cancer, Thiopurine Methyltransferase gene, Treatment Response, Polymorphism.

References

1. Al-Sarraf M. Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control 2002; 9(5): 387-99.

2. Weinshilboam R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos. 2001; 29:601-5.

3. Berthem G Katzung. Basic and Clinical Pharmacology 11th edi.; P-59

4. Nebert DW. Role of genetics and drug metabolism in human cancer risk. Mutat Res. 1991;247(2):267–281.

5. Guengerich FP. Enzymatic oxidation of xenobiotic chemicals. Crit Rev Biochem Mol Biol. 1990;25(2):97-153.

6. Basic and Clinical Pharmacology, Berthem G Katzung, 11th edition, table 4-4, p-62.

7. Marsh S, McLeod HL. Cancer pharmaco-genetics. Br J Cancer. 2004;90(1):8-11.

8. Ross CJ, Katzov-Eckert H, Dube MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009;41(12):1345-9.

9. Hiratsuka M, Agatsuma Y, Mizugaki M. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green. Mol Genet Metab. 1999;68(3):357-62.

10. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997;126(8):608-14.

11. Lennard L, Lilleyman J S, Van Loon J. Genetic variations in response to 6-mercaptopurine for childhood acute leukaemia. Lancet. 1990;336:225-229.

12. Weinshilboum RM. Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase. Cell Mol Neurobiol. 2006;26(4-6):539-61.

13. Grant A, Cauffiez C, Ranault N, et al. Characterization of novel defective thiopurine S-methyl transferase allelic variant. Biochem Pharmacology. 2008;76; 404-15.

14. Ando Y, Hasegawa Y. Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metab Rev. 2005;37(3):565-74.

15. Coulthard SA, Hogarth LA. The effect of thiopurine methyl transferase expression on sensitivity to thiopurine drugs. Mol Pharmacology. 2002;62:102-109.

16. Murugesan R, Vahab SA, Patra S, et al. Thiopurine S-methyltransferase alleles, TPMT(*)2, (*)3B and (*)3C, and genotype frequencies in an Indian population. Exp Ther Med. 2010;1(1):121-127.

Call For Paper Volume 12 Issue 10 November 2024

The JMSCR is accepting manuscripts for its coming issues to be Publish Volume 12 Issue 11 November 2024 the JMSCR invites authors to submit manuscripts Reporting original medical research, original article, research article, case report, systematic reviews, or educational Innovations for publication for the coming issues that will be released in Volume 12 Issue 11 November 2024. Types of manuscripts suitable for JMSCR include: Medical research, Clinical research Educational Innovation, Brief Report, Reviews on Teaching In keeping with high quality scholarship, Read More.....

https://jmscr.igmpublication.org/ems/index.php/jmscr/about/submissions

If any difficulty you can also submit to: This email address is being protected from spambots. You need JavaScript enabled to view it.

JMSCR Menu

Impact Factor SJIF 2024: 7.892

https://sjifactor.com/passport.php?id=1725

Crossref - DOI

Crossref - DOI Prefix: 10.18535/jmscr

Editorial Policy

Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not ..

Frequency of Publication

JMSCR is published as monthly journal with 12 issues per year. Special editions are also planned subjected to the scope and need....

Submission of Articles

Authors are invited to submit their research articles, review papers, Case Report properly formatted as per the author guidelines.........

Search